Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10 (2024)

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-12 pm EDT			5-day change	1st Jan Change
44.64 ^USD	+7.83%		+7.70%	-6.65%

Jun. 12	Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025	MT
Jun. 12	Ultragenyx Pharmaceutical Launches Equity Offering	MT

Presenter SpeechSalveen Richter (Analysts)Good morning. Thank you so much for joining us. Real...

This article is reserved for subscribers

To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Ultragenyx Pharmaceutical Inc.

Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025	Jun. 12	MT
Ultragenyx Pharmaceutical Launches Equity Offering	Jun. 12	MT
Ultragenyx Pharmaceuticals to Seek Accelerated Approval of Genetic Disease Treatment	Jun. 12	DJ
Sector Update: Health Care Stocks Ease Late Afternoon	Jun. 12	MT
Sector Update: Health Care	Jun. 12	MT
Ultragenyx, Mereo BioPharma Shares Rise as Bone Disorder Drug Shows Reduced Fracture Rate	Jun. 12	MT
Sector Update: Health Care Stocks Rise Premarket Wednesday	Jun. 12	MT
Sector Update: Health Care	Jun. 12	MT
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study	Jun. 12	CI
Ultragenyx, Mereo BioPharma Say Phase 2 Study of Bone Disorder Drug Showed Reduced Fracture Rate	Jun. 12	MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10:00 AM	Jun. 11
Goldman Sachs Upgrades Ultragenyx Pharmaceutical to Buy From Neutral, Raises Price Target to $67 From $56	Jun. 06	MT
Cantor Fitzgerald Adjusts Price Target on Ultragenyx Pharmaceutical to $115 From $107, Maintains Overweight Rating	May. 31	MT
Stifel Adjusts Price Target on Ultragenyx Pharmaceutical to $127 From $124, Maintains Buy Rating	May. 31	MT
Baird Raises Price Target on Ultragenyx Pharmaceutical to $72 From $68, Maintains Outperform Rating	May. 31	MT
Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $48 From $47, Keeps Neutral Rating	May. 31	MT
Transcript : Ultragenyx Pharmaceutical Inc. - Special Call	May. 30
Ultragenyx Pharmaceutical Inc. Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia	May. 30	CI
Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	May. 14	MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM	May. 14
Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating	May. 03	MT
Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q1 Revenue $108.8M	May. 02	MT
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024	May. 02	CI
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI

Chart Ultragenyx Pharmaceutical Inc.

Duration

Period

More charts

Company Profile

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Companyâs four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of hom*ozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

Sector

Calendar

2024-06-18 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Ultragenyx Pharmaceutical Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.64USD

Average target price

90.24USD

Spread / Average Target

+102.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ULTRAGENYX PHARMACEUTICAL INC.	-6.65%	3.44B
VERTEX PHARMACEUTICALS INCORPORATED	+16.93%	124B
REGENERON PHARMACEUTICALS, INC.	+17.01%	109B
BIONTECH SE	-7.23%	23.84B
ARGENX SE	+1.98%	22.42B
GENMAB A/S	-14.29%	17.5B
BEIGENE, LTD.	-6.79%	16.61B
WUXI APPTEC CO., LTD.	-37.63%	16.43B
NEUROCRINE BIOSCIENCES, INC.	+2.17%	13.4B
SAREPTA THERAPEUTICS, INC.	+24.42%	11.47B

Bio Therapeutic Drugs

Stock Market
Equities
RARE Stock
News Ultragenyx Pharmaceutical Inc.
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10

As early as today, start finding the best investment opportunities! Optimize my profits

"); InvestingChannelQueue.push(function() { aICTags["oop"] = ic_page.defineOutOfPageTag("4Traders/quotepages","zppOOP"); aICTags["oop"].setKval({"adslot":"d_OOP_1"}); aICTags["oop"].render(); }); while (aAdsQueue.length) { (aAdsQueue.shift())(); } InvestingChannelQueue.push(function() { displayViewableAds('InvestingChannel'); $( window ).scroll(function() { displayViewableAds('InvestingChannel'); }); }); }gaEvent('adspv', 'InvestingChannel', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '15672076');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });